Cost-effectiveness of cervical cancer prevention

Clin Obstet Gynecol. 2013 Mar;56(1):55-64. doi: 10.1097/GRF.0b013e3182823797.

Abstract

Cost-effectiveness analyses are an important tool for the evaluation and modification of many health care services. Given the variety of screening tests and treatments available for cervical cancer screening and prevention, the costs associated with these options and with their alternatives, and the differences in resources and settings in which these tests are applied worldwide, cost-effectiveness analyses evaluation can be very useful to help determine best practices.

Publication types

  • Review

MeSH terms

  • Cost-Benefit Analysis
  • Developing Countries / economics
  • Early Detection of Cancer / economics*
  • Female
  • Human Papillomavirus DNA Tests / economics
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Humans
  • Markov Chains
  • Papillomavirus Infections / diagnosis
  • Papillomavirus Vaccines / economics
  • Quality-Adjusted Life Years
  • United States
  • Uterine Cervical Neoplasms / diagnosis*
  • Uterine Cervical Neoplasms / prevention & control*
  • Vaginal Smears / economics*

Substances

  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Papillomavirus Vaccines
  • human papillomavirus vaccine, L1 type 16, 18